Iridex (IRIX) Income from Discontinued Operations (2012)

Iridex (IRIX) posted quarterly Income from Discontinued Operations of 149000.0 for Q4 2012, up 178.42% quarter-over-quarter from 190000.0 in Q3 2012.

Iridex (IRIX) Income from Discontinued Operations (2012) Analysis & Trends

Iridex's Income from Discontinued Operations history runs 1 years deep, the most recent figure standing at 149000.0 for Q4 2012.

In Q4 2012, Income from Discontinued Operations changed N/A year-over-year to 149000.0; the TTM figure through Sep 2013 stood at 149000.0 (changed N/A YoY), while the FY2012 annual figure was 264000.0, down 156.29% from the prior year.
Income from Discontinued Operations for Q4 2012 stood at 149000.0, up from 190000.0 in the prior quarter.
The five-year high for Income from Discontinued Operations was 149000.0 in Q4 2012, with the low at 190000.0 in Q3 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Income (Discontinued) (Qtr)
1	Abbott Laboratories	199.07 Bn	193.46 Bn	7.27 Bn	-
2	Stryker	127.90 Bn	124.43 Bn	4.50 Bn	-
3	Medtronic	118.84 Bn	109.62 Bn	6.41 Bn	-
4	Boston Scientific	73.33 Bn	72.79 Bn	3.85 Bn	-
5	Edwards Lifesciences	51.93 Bn	47.68 Bn	1.35 Bn	-
6	Dexcom	34.46 Bn	32.51 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.91 Bn	31.81 Bn	2.18 Bn	-
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	-
9	Steris	23.12 Bn	22.64 Bn	684.20 Mn	-
10	Iridex	13.32 Mn	8.64 Mn	4.30 Mn	-

Download Data